M&A Focus: Biotechnology
|
|
- Esmond Beasley
- 6 years ago
- Views:
Transcription
1 Month Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology, hoping to remain relevant Pharmaceutical companies could lose more than $200.0 million in revenue because of patent expirations With huge piles of cash on hand, largecap pharmaceutical companies, known as Big Pharma, have shown strong interest in acquiring biotech companies with promising drug candidates to help bolster thinning pipelines in the wake of patent expirations. Because of this Patent Cliff, the largest pharmaceutical companies are anticipated to lose about $29.0 billion in revenue this year. After a relatively quiet 2010 for M&A activity, 2013 will be crucial turning point for many pharmaceutical goliaths, especially in the United States and Europe. In the past few years, major biotech firms including Amgen, Roche Holding AG, Merck KGaA and Sanofi have been at the forefront of M&A activity. For example, in 2009, Switzerland-based pharmaceutical giant Roche Holding AG acquired full ownership of Genentech Inc. for an estimated $46.8 billion. Genentech is considered one of the founders of the Biotechnology industry, and it continues to lead the industry with a strong product portfolio and research and development (R&D) activities. In today s environment, which is characterized by the sluggish biotech IPO market, stretched R&D funding and limited venture capital for biotech startups, it is more difficult to replicate the success of biotech giants like Amgen, Gilead Sciences and Biogen Idec. A number of roadblocks stand in the way of revenue growth including patent Performance of key industries related to biotech M&A activity Industry 2013 Revenue ($billion) Annualized growth ( ) Projected annualized growth ( ) Biotechnology in the US % 8.9% Brand Name Pharmaceutical Manufacturing in the US % 1.9% Generic Pharmaceutical Manufacturing in the US % 6.4% Global Biotechnology % 9.2% Global Pharmaceutical Manufacturing 1, % 3.5% Contract Research Organizations % 11.0% SOURCE: info@ibisworld.com
2 May expirations, reimbursement pressure, price cuts, stringent regulations and high costs associated with internally developing new treatments. Therefore, Big Pharma players are trying to acquire and collaborate with small and mediumsized biotech firms with promising, high-margin biologic drugs. During the five years to 2018, IBISWorld projects that M&A activity will continue, providing new prospects for investors seeking to expand their portfolios. Patent Cliff driving consolidation A major driver of mounting M&A activity is the Patent Cliff that Big Pharma companies have been tiptoeing around since The Patent Cliff refers to the phenomena of major blockbusterbranded drugs (e.g. Lipitor for Pfizer, and Plavix and Avapro for Bristol-Myers Squibb) losing patent protection, which allows generic versions of these drugs to be made, increasing competition. During the five years to 2018, global pharmaceutical companies are at risk of losing more than $200.0 billion in revenue because of patent expirations, according to EvaluatePharma, the premier provider of pharmaceutical and biotech analysis. For example, from 2010 to 2012, drugs that make up about 42.0% of Pfizer s pharmaceutical revenue lost patent protection. For Pfizer, the biggest patent loss was its 2011 patent expiration for the cholesterol-lowering drug Lipitor, which accounts for about 14.0% of the company s revenue and is one of the best-selling drugs in the world. Due to patent loss on Lipitor and other drugs, Pfizer s revenue contracted 21.6% in This resulted in the company trimming costs by slashing its labor force. Because of projected competition and loses, Big Pharma companies are seeking to acquire small to mid-sized biotech companies with promising drug candidates. Biotech companies have a strong competitive advantage over generic pharmaceutical manufacturers due to the high costs of developing biological drugs. Biologic drugs are made from complex biological processes and are therefore more expensive to develop and manufacture than drugs produced via chemical synthesis. While the FDA approved only 21 new drugs in 2010, the number of new drug approvals grew to 30 in 2011 and 39 in The faster approval of new drugs by the FDA paves the way for the commercialization of new drugs, particularly those that treat rare diseases and target unmetmedical needs. In June 2012, the U.S. Supreme Court ruled to uphold a law that will keep the 12-year exclusivity period intact. This shed some light on the long-debatable exclusivity period issue granted to original, biologic-drugs manufacturers. Unlike brand name pharmaceutical companies that have faced competition from generic manufacturers since the approval of the Hatch-Waxman Act in 1984, biotech companies have not had a formal regulatory pathway for the approval of biosimilar drugs (e.g. follow-on biologics). The 12-year exclusivity period is expected to benefit biotech companies because it could have been shortened to five years; however, the 12-year guarantee will provide investors with the predictability that is required when forecasting future product sales for biological drugs in development. Consequently, investor confidence is expected to improve and more available financing is projected to follow. Opportunities from emerging markets In addition to rising M&A activity in the domestic market, Big Pharma companies are penetrating burgeoning emerging markets by acquiring foreign firms. With anemic revenue growth in developed markets, triggered by pricing
3 May pressures and higher tax rates, global companies are looking to offshore operations to emerging markets that have less expensive R&D environments. Given the growing aging population, the prevalence of chronic diseases and a growing middle class with increased disposable income, emerging markets that are attracting investors include China, India and Brazil. In fact, in 2011, emerging markets accounted for about 20.0% of global pharmaceutical sales, according to the Economist Intelligence Unit database. For example, one of the world s largest biotech companies Roche Holding AG generates about 28.0% of its pharmaceuticals revenue from emerging markets, compared to 37.0% derived from the United States and 25.0% from Europe. In 2011, Amgen completed the acquisition of privately held Brazilian pharmaceutical company Bergamo and agreed to reacquire its rights in Brazil to products that were previously granted to another company. Because of these transactions, Amgen is expected to have gained an important presence in Brazil and direct access to one of the fastest-growing pharmaceutical markets in the world. Amgen also acquired Mustafa Nevzat Pharmaceuticals, a privately held Turkish company. This acquisition is estimated to have expanded Amgen s footprint in Turkey and its surrounding emerging markets. Additionally, global-biotech giant Merck continued its biotechnology expansion in China by acquiring Beijing Skywing Technology Co., a leading supplier of cell-culture media products and bioreactors for the Chinese biopharmaceutical industry. Given low interest rates and considerable cash on hand, global pharmaceutical and biotech companies will continue mergers, consolidations and partnerships throughout the world. Growing demand for biologic drugs With fewer blockbuster acquisitions expected in coming years, Big Pharma companies are seeking to acquire small and mid-sized companies focused on developing drugs for more targeted populations and rare diseases. The aging population and rising prevalence of chronic disease have spurred demand for innovative treatments and boosted demand for biologic drugs, pushing companies to search for strategies to expand their pipelines. Companies like Sanofi and Celgene are strengthening their market position in the oncology market though acquisitions. This market remains a sought-after therapeutic area. As such, in March 2012, one of the major US stand-alone biotechnology companies, Amgen, acquired Micromet Inc., a publicly held biotech company focused on the development and commercialization of antibody-based therapies for cancer treatment. Although Micromet does not have an approved product on the market, this deal, valued at about $1.16 billion, was a strategic move for Amgen s oncology pipeline because it provides a novel, technological platform with multiple possible applications. Another example of this was Sanofi s acquisition of Genzyme, a leading biotech group specializing in the treatment of rare diseases, renal diseases, endocrinology, oncology and biosurgery, which was completed in This expanded Sanofi s presence in the global biotechnology arena, and boosted the company s revenue and product pipeline. Other therapeutic areas projected to see increased M&A activity are central nervous system disorders, diabetes, Hepatitis C, immunology and inflammation. There are more than 400 biotech products and vaccines currently in clinical trials, attempting to target
4 May About IBISWorld Inc. Recognized as the nation s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit or call Contact: Savannah Haspel VP, Public Relations IBISWorld Phone: savannahh@ibisworld.com more than 200 diseases, according to the Biotechnology Industry Organization. Risk IBISWorld assesses risk scores based on a scale of one to nine, with one representing the lowest risk and nine representing the highest. In 2013, overall risk in the Biotechnology industry is projected to be 4.27, which is considered a medium-low risk level. The two most significant factors contributing to the risk score are R&D expenditure and regulation. As R&D expenditure increases, development in the industry also advances, boosting sales and demand for novel products. During 2013, R&D is expected to increase slowly, which is an opportunity for the industry. At the same time, regulation is projected to increase slowly in 2013, and this may threaten the industry as any change in the regulatory environment creates volatility, affecting companies bottom lines. During the five years to 2018, growth risk is forecast to remain low with a projected annualized revenue growth rate of 8.9%. Outlook In the five years to 2018, IBISWorld projects M&A activity to continue, with a considerable boost in in-licensing activities and partnerships for the development of new drug candidates. With Big Pharma s declining appetite for high-profile mega deals, smaller acquisitions are forecast to prevail during the next few years. For example, companies like Spectrum, a growing cancer-drug manufacturer, are already drawing investors attention and becoming attractive targets for future M&A deals. After years of incurring losses, Spectrum recorded profitability in 2011, and its revenue is estimated to have almost quadrupled from $74.0 million in 2010 to $266.0 million in Spectrum s Fusilev, a drug aimed to treat osteosarcoma and colorectal cancer, and Zevalin, which treats non- Hodgkin lymphoma, are the biggest revenue drivers for the company. Furthermore, biotech and pharmaceutical companies are increasingly involved in in-licensing and collaborations that help alleviate risks and the extremely high costs associated with the development of new drugs. In addition to sharing similar goals or fields of interest, in-licensing enables companies to use their expertise to achieve the best outcomes in terms of high revenue and profitability. In today s challenging environment of raising cash to survive, small biotech companies are continually seeking deals with larger players that are ready to invest in promising drug candidates. With the much-anticipated, lukewarm market for biopharma IPOs, more players will try to establish partnerships and collaborations. For example, a number of biotech and pharmaceutical companies are already outsourcing services to contract research organizations (CROs), which conduct clinical trials and research, manage data results, provide regulation adherence services, and help develop and formulate new products. Bolstered by rising demand from biopharmaceutical companies, the advantages of strategic partnerships are likely to rise in the five years to 2018 as CROs can provide clients with cost savings, accelerated development and reduced risk. Given favorable demographic trends, such as the aging population and the prevalence of chronic diseases, demand for medical treatments will continue to rise. However, this does not mean the industry will be free of more extensive changes during the next five years. Industry activity such as new market opportunities and anticipated losses due to patent expirations will cause biopharmaceutical companies to continue frequent M&A activity in coming years.
5 At IBISWorld we know that industry intelligence is more than assembling facts. It is combining data with analysis to answer the questions that successful businesses ask. Identify high growth, emerging and shrinking markets Arm yourself with the latest industry intelligence Assess competitive threats from existing and new entrants Benchmark your performance against the competition Make speedy market-ready, profit-maximizing decisions Who is IBISWorld? We are strategists, analysts, researchers and marketers. We provide answers to information-hungry, time-poor businesses. Our goal is to give you the real-world answers that matter to your business in our 700 US industry reports. When tough strategic, budget, sales and marketing decisions need to be made, our suite of Industry and Risk intelligence products give you deeply researched answers quickly. IBISWorld Membership IBISWorld offers tailored membership packages to meet your needs. Join and become an industry expert! Disclaimer This product has been supplied by IBISWorld Inc. ( IBISWorld ) solely for use by its authorized licensees strictly in accordance with their license agreements with IBISWorld. IBISWorld makes no representation to any other person with regard to the completeness or accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability (save for liability which cannot be lawfully disclaimed) for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the data or information contained herein. Copyright in this publication is owned by IBISWorld Inc. The publication is sold on the basis that the purchaser agrees not to copy the material contained within it for other than the purchasers own purposes. In the event that the purchaser uses or quotes from the material in this publication in papers, reports, or opinions prepared for any other person it is agreed that it will be sourced to: IBISWorld Inc. Copyright IBISWorld Inc.
Top Five Distressed US Industries
WWW.IBISWORLD.COM January April 2017 2014 1 Top Follow Five on Distressed head on Master US Industries page A April 2017 By Jon DeCarlo, Darshan Kalyani, Kelsey Oliver and Iris Peters All five of these
More informationSix Industries Affected by Changes in US & China Trade Policy
WWW.IBISWORLD.COM January August 2017 2014 1 US Follow & China on head Trade Relations Master page A August 2017 Six Industries Affected by Changes in US & China Trade Policy By Brian Sayler, Merry Zhao,
More informationTop 5 US Export and Import Commodities
WWW.IBISWORLD.COM Special Report Month 2012 1 Follow on head on Master page A Special Report July 2012 Top 5 US Export and Import Commodities By Josh McBee and Justin Waterman Dominated by oil, cars and
More informationLuxury spending drives recovery
WWW.IBISWORLD.COM Special Report April 2011 1 Special Report April 2011 By Nikoleta Panteva As the economy slowly improves and purse strings loosen, American shoppers increasingly head to the high-end
More informationTop 5 Consolidating Industries
WWW.IBISWORLD.COM January August 2015 2014 1 Top Follow 5 Consolidating head Master Industries page A August 2015 By Darryle Ulama, Andrew Alvarez and Nick Petrillo By analyzing more than 1,000 US industries
More informationHigh Demand Means Rising Tech Prices
WWW.IBISWORLD.COM August 2014 1 August 2014 High Demand Means Rising Tech Prices By Daniel Krohn Despite the broader trend of falling computer and hardware prices, buyers are seeing these four products
More informationFive Top-Performing Niche Industries in the US
WWW.IBISWORLD.COM January April 16 14 1 Follow on head on Master page A April 16 Five Top-Performing Niche Industries in the US By Jack Curran, Dmitry Diment, Evan Hoffman, Viraj D Costa and Taylor Palmer
More informationIndirect Influence: Drive your Marketing Spend with Procurement
Office Consumables Utilities Print Facilities Management Telecoms IT (Hardware & Software) Logistics/Distribution Travel Professional Services Temporary Labor Marketing WWW.IBISWORLD.COM November 2016
More informationFame Factor: Five Industries Affected by Pop Culture Trends
WWW.IBISWORLD.COM January July 2017 2014 1 Follow on head on Master page A July 2017 Fame Factor: Five Industries Affected by Pop Culture Trends By Anya Cohen Favored consumer trends and celebrity influence
More informationGig Economy: Industries Embracing Mobile-Enabled Business Models
WWW.IBISWORLD.COM January 2017 2014 1 January 2017 Mobile Follow on Technology s head on Master Influence page on A the Gig Economy Gig Economy: Industries Embracing Mobile-Enabled Business Models By Madeline
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health January 2018 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationEvolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors
HEALTHCARE Evolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors By Melissa Zebrowski Table of Contents Melissa Zebrowski Melissa Zebrowski has seven years of experience
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationPatricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, (732)
Pharmaceutical Technology Patricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, pvanarnum@advanstar.com, (732) 346-3072 Biopharmaceutical Industry in 2012: Optimism on the Rise
More informationBaby Boom: 5 Baby-Related Industries Poised for Post-Recession Growth
WWW.IBISWORLD.COM October 2013 1 October 2013 Baby Boom: 5 Baby-Related Industries Poised for Post-Recession Growth By Jocelyn Phillips Tech-savvy Generation Y parents are highly individualized consumers
More informationData Protection for Biologics: Balancing Innovation Incentives and Cost Savings Henry Grabowski
Data Protection for Biologics: Balancing Innovation Incentives and Cost Savings Henry Grabowski Health Industry Forum Washington, DC June 11, 2009 What is Data Protection? Data protection is the period
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationMargins of pharmaceutical companies are continuing to decline the future lies in new ecosystems
Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationPrimer: The Biotechnology Industry Han Zhong l September 2011
Primer: The Biotechnology Industry Han Zhong l September 2011 Introduction The budding biotechnology industry covers a wide range of human health biologic products and technologies that are created by
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationEVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE
, 09 MAY 2018 EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE 55% INCREASE IN GROUP REVENUES STRONG UNDERLYING OPERATIONAL PERFORMANCE WITH NEW BUSINESS MIX AFTER APTUIT ACQUISITION
More informationCollaborative Development Financing
Collaborative Development Financing 14 by Warren Nachlis and Wendy Brasunas The Growth of the Biotechnology Industry Pharmaceutical drug development is a risky and very expensive process. According to
More informationMcKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?
McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationINVESTOR PRESENTATION 2018
INVESTOR PRESENTATION 2018 IMMUNOPRECISE ANTIBODIES, LTD. UNIT 3204-4464 MARKHAM STREET VICTORIA, BRITISH COLUMBIA V8Z 7X8, CANADA IMMUNOPRECISE.COM 1 Disclosures DISCLAIMER This presentation is not, and
More informationUnderstanding How The Indian Pharmaceutical Industry Works Part 3
Understanding How The Indian Pharmaceutical Industry Works Part 3 Key Performance Indicators Pharmaceutical Sector Sales & Marketing Marketing always starts with the customer and ends with the customer
More informationInvitrogen. MedImmune. Biogen Idec. Genentech. Merck-Serono. Novartis. Gilead Sciences UCB. Available by Company!
MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS This report is being updated. Subscribers will receive complimentary copies of the previous edition while the new report is in preparation.
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationList of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1
Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationISPE: Pharma Industry Outlook
ISPE: Pharma Industry Outlook ANDREW D. SKIBO Head of Global Biologics Operations & Global Engineering MedImmune/AstraZeneca Chairman, ISPE Board of Directors October 7, 2015 Linking Past ISPE Drivers
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationTrends and Transformations Facing Pharma in 2017
TH E Y E A R A H E A D : Trends and Transformations Facing Pharma in 2017 Table of Contents 2 Introduction Trend 1: The Rise of Generics Trend 2: Rx Volumes Spike Trend 3: Rise of Cold-Chain Logistics
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationWhat Is The Largest Issue Facing Pharmaceutical Companies Today
What Is The Largest Issue Facing Pharmaceutical Companies Today For an industry as data-intensive as pharmaceuticals, innovations in 'big data' and tackle some of the biggest issues they are facing in
More informationCompany Research. Dr Reddy s Laboratories- BUY with a Target of Rs 1,962. Investment overview- Business Overview-
Date-16-07-2012 Dr Reddy s Laboratories- BUY with a Target of Rs 1,962 Investment overview- Shareholders Information Global Generics grew by 68% to Rs 70,243mn in FY12 from Rs 53,340mn in Fy11. Therefore
More informationIndian CRAMS players to cram in growth: CARE Ratings
January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register
More information10 US Industries to Rise and Fall in 2017
WWW.IBISWORLD.COM December January 2016 2014 1 US Follow Industries on head Set on to Master Rise and page Fall Ain 2017 December 2016 10 US Industries to Rise and Fall in 2017 By Madeline Hurley, Madeline
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationGlobal Gene Therapy Market Report -2026
Global Gene Therapy Market Report -2026 July 2018 Table of Contents 1 Executive Summary 2 Gene Therapy: Overview Viral Vectors for Gene Therapy Viral Vectors Non-Viral Vectors Types of Gene Therapy Somatic
More informationWhite paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act
White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act Published: July 2014 Author: Anantharaman Kavassery Viswanthan Anantharaman Kavassery Viswanathan
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationAn Economic Analysis of Generic Drug Usage in the U.S.
September 2011 $931 Billion SAVINGS An Economic Analysis of Generic Drug Usage in the U.S. EXECUTIVE SUMMARY As government leaders in Washington and across the country look for ways to cut health care
More informationPHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has
More informationVISION & STRATEGY FIC LIC. Interview with the President
VISION & STRATEGY Interview with the President A conversation with Isao Teshirogi, President and CEO about the Shionogi Growth Strategy 2020 (SGS2020) VISION & STRATEGY SGS2020 Growth Strategies Under
More informationPromotion and Development Collaborations Between Established Players
Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com
More informationDRAFT DOCUMENT FINAL COPY TO REFLECT CONFIRMED. Embed Innovations to Transform Your R&D Procurement Model and. Drive Scientific Activities Efficiency
Embed Innovations to Transform Your R&D Procurement Model and Drive Scientific Activities Efficiency April 30 May 1, 2018 Boston, US This conference exceeded all of my expectations. The topics, speakers
More informationTable of Contents. Presented by
Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com May 2017 TABLE OF CONTENTS
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationCommerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationFinancial Advisory. Valuation Services. Life Science Industry
Financial Advisory Services Life Science Industry Fact sheet: Life Science Industry Services Many life sciences companies struggle with nurturing the promise of innovative discoveries in a volatile market
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationProof of Concept. Achieve your molecule s full potential
Proof of Concept Achieve your molecule s full potential Table of contents 01 Maximize the value of your molecule 02 Enhance your resources and 03 Increase your speed and efficiency 04 your product s market
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationPROVECTUS BIOPHARMACEUTICALS INC. ANALYST BRIEF A NEW FRONT AGAINST CANCER
Summary Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) is a biopharmaceutical company whose planned principal operations is focusing on developing minimally invasive products for the treatment of psoriasis
More informationGLOBAL MARKETS FOR DRUG REPURPOSING
GLOBAL MARKETS FOR DRUG REPURPOSING PHM175A January 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-202-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationCareer Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
More informationBioProcess Technology Consultants, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994
, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994 Who We Are The biopharmaceutical and biotherapeutic development experts We are a team of results-oriented professionals assisting
More informationGlobal and China Monoclonal Antibody Industry Report, Dec. 2013
Global and China Monoclonal Antibody Industry Report, 2013-2017 Dec. 2013 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis,
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationBIOPHARMACEUTICAL BUSINESSES
BIOPHARMACEUTICAL BUSINESSES Our Biopharmaceuticals businesses consist of four patientcentric, customer-facing business units. The business units are responsible for further clinical development and lifecycle
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationICON plc. 10th Jan Ciaran Murray CEO Steve Cutler CEO Designate. JP Morgan 35TH Annual Healthcare
ICON plc Ciaran Murray CEO Steve Cutler CEO Designate JP Morgan 35TH Annual Healthcare 10th Jan 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may
More informationGlobal and China Biopharmaceutical Industry Report, 2010
Global and China Biopharmaceutical Industry Report, 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound
More informationto acquire Investor And Analyst Call Presentation January 4, 2008
to acquire Investor And Analyst Call Presentation January 4, 2008 Safe Harbor Statement The following information contains, or may be deemed to contain, forward looking statements (as defined in the U.S.
More information14 May Evotec Q1 2013: Driving Innovation Efficiency
14 May 2013 Evotec Q1 2013: Driving Innovation Efficiency STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY EVOTEC S DRUG DISCOVERY PLATFORM GENERATES GROWTH NEW HORMONE IDENTIFIED
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationValuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia
Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 0 Biosimilars Asia Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion Venture Valuation Independent assessment
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationStrategic Partnership
Strategic Partnership William J. Gole What is the issue? While strategic partnerships have grown in popularity in recent years, they often do not meet their intended objectives. Why is it important? Without
More informationProduct lifecycle management in one site
Product lifecycle management in one site Today s world provides multiple opportunities for a biopharma company. An aging global population and the prevalence of chronic and communicable diseases are creating
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationPart I: Life Sciences Overview
Part I: Life Sciences Overview Biotechnology Introduction The Drug Development Process Genomics/Proteomics Agricultural Biotechnology Pharmaceuticals Market Size & Current Status Major Opportunities Major
More informationAutomakers and Auto Parts manufacturers
Last updated: July 13, 2011 Rating Methodology by Sector Automakers and Auto Parts manufacturers 1. Business base Susceptible as it is to business fluctuations, the demand for new automobiles is relatively
More informationA Biotech Blockbuster in the $60 Billion Pet Industry. A Biotech Blockbuster in the $60 Billion Pet Industry
A Biotech Blockbuster in the $60 Billion Pet Industry Artana Therapeutics: Off the Radar and Undervalued Our next profile is a unique biopharma that is literally for the dogs, and that is a good thing
More informationStrategic Overview of the Biotechnology Industry
Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationHow Biosimilars Track a Unique Sales Path:
How Biosimilars Track a Unique Sales Path: Three Case Studies to Help Anticipate Biosimilar Entry in Your Market Judith Kulich and Emily Jin How Biosimilars Track a Unique Sales Path: Three Case Studies
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationnovel drug molecule for the treatment of Chronic Pain
novel drug molecule for the treatment of Chronic Pain Pandemic Problem Chronic Pain need adequate non opioid novel drug molecule to treat Chronic pain still a pandemic in the 21st century Chronic pain
More informationInfor Life Sciences. Transform your business. Deploy and adapt quickly. Meet your specific needs
Infor Life Sciences With Infor, we ve reduced complexity and increased throughput, while being able to take advantage of our existing infrastructure investments. Matt Ottmer, Vice President of Global Supply
More informationTrump Biotech Special: A $7 Stock with Yuge Potential. Trump Biotech Special: A $7 Stock with Yuge Potential
Trump Biotech Special: A $7 Stock with Yuge Potential Xenon Pharmaceuticals: Vastly Undervalued With Yuge Potential It seems appropriate after all but secured the Republican nomination to highlight a small
More informationSpotlight on: Staffing and retention. Pharma, biotech and medical devices
Spotlight on: Staffing and retention Pharma, biotech and medical devices A US perspective 2013 Expansion, mergers, acquisitions and competition have impacted on salary and benefit expectations, and the
More informationUBS 2007 Global Life Sciences Conference. September 24, 2007
UBS 2007 Global Life Sciences Conference September 24, 2007 Safe Harbor This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationGlobal Pharmaceutical Industry Profile 2012
2012 1. Global Pharmaceuticals Market 1.1 Pharmaceutical Sector (Market) Performance The global pharmaceutical market has shown steady growth throughout the years. In particular, the market size of the
More informationPfizer Completes Acquisition of Hospira
For immediate release: September 3, 2015 Media Contact: Joan Campion (212) 733-2798 Investor Contact: Chuck Triano (212) 733-3901 Pfizer Completes Acquisition of Hospira Creates a leading Global Established
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationIntellectual property: The driving force for growth and funding
Judith E. Schneider is Chairman and Chief Executive Officer of The BPI Group Limited, a leading professional services firm providing strategic advisory and business plan development services to emerging
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More information